Huberman joins Hims & Hers board — plus $8.5M a year in advisory and ad deals
What's the deal? Hims & Hers Health appointed neuroscientist and Stanford professor Andrew Huberman, 51, to its board on November 4, 2026, expanding the board from nine to ten directors. Alongside the seat, Huberman signed overlapping commercial deals: a two-year advisory arrangement worth $3.5 million a year, up to $1 million a year for ad videos, and $5 million a year for up to three years to his co-owned Scicomm Media.
Who is he? Huberman hosts Huberman Lab , described by the company as the most popular health and science podcast in the world, and wrote the number-one New York Times bestseller Protocols . His Stanford lab has studied brain development, neural plasticity, and the neural mechanisms of stress.
What changes? Beyond governance, Huberman will serve as a scientific and brand marketing advisor and provide marketing support through his podcast. His board cash retainer is $50,000, with a $250,000 equity award.
Why now? The appointment lands as Hims pushes beyond its core, adding branded obesity drugs from Novo Nordisk and Eli Lilly and preparing a Peptides+ offering. Third-quarter revenue rose 49% year over year, but subscribers fell by 100,000 sequentially and the company lowered its adjusted-profit outlook — putting marketing efficiency in focus.
What could go wrong? The filing states Huberman does not meet New York Stock ExchangeDealroom has a profile for this one. Try Dealroom → independence requirements, and he sits on no board committee. The mix of advisory pay, board oversight, and podcast advertising makes clear disclosure and perceived editorial independence important.
The signal: Hims is fusing a trusted health communicator's audience with both its governance and its paid promotion — a bet that reaching consumers through a credible science voice can offset slowing subscriber growth.
Read more: sec.gov
Image credit: Generated with Gemini